Paraoxonase1-192 polymorphism modulates the nonfatal myocardial infarction risk associated with decreased HDLs

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 21, Issue 3, 2001, Pages 415-420

  Sentí, Mariano ^a,b   Tomás, Marta ^a   Marrugat, Jaume ^a   Elosua, Roberto ^a  

^a UNIVERSITAT POMPEU FABRA   (Spain)

^b INST MUNIC D INVESTIGACIO MEDICA   (Spain)

Author keywords

HDL; Myocardial infarction; Paraoxonase; PON1 genotypes

Indexed keywords

ARYLDIALKYLPHOSPHATASE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ALLELE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE DOSAGE; GENE LOCUS; GENETIC POLYMORPHISM; GENOTYPE; HEART INFARCTION; HUMAN; LIPOPROTEIN BLOOD LEVEL; LIPOPROTEIN DEFICIENCY; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0035094480     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.21.3.415     Document Type: Article

References (36)

1. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein
2. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family
3. Paraoxonase: Biochemistry, genetics and relationship to plasma lipoproteins
4. Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes
5. Paraoxonase gene polymorphism in Japanese subjects with coronary heart disease
6. 142Arg variant of the human paraoxonase (HUMPONA) gene polymorphism is associated with an increased risk for coronary artery disease in the Japanese
7. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease
8. The Gln-Arg 191 polymorphism of the human paraoxonase gene (HUMPONA) is not associated with the risk of coronary heart disease in Finns
9. The paraoxonase Gln-Arg 192 polymorphism in subjects with ischaemic heart disease
10. The Gln/Arg polymorphism of human paraoxonase (PON 192) is not related to myocardial infarction in the ECTIM Study
11. The Gln-Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients
12. Risk of myocardial infarction associated with Gln/Arg 192 polymorphism in human paraoxonase gene and diabetes mellitus
13. High prevalence of cardiovascular risk factors in Gerona, Spain, a province with low myocardial infarction incidence
14. Acute myocardial infarction case fatality, incidence and mortality rates in a population registry in the province of Girona, Spain, 1990 to 1992
15. A simple salting-out procedure for extracting DNA from human nucleated cells
16. The molecular basis of the human serum paraoxonase activity polymorphism
17. Long-term predictors of subsequent cardiovascular events with coronary artery disease and "desirable" levels of plasma total cholesterol
18. Effect of serum lipid concentration on restenosis after successful de novo percutaneous transluminal coronary angioplasty in patients with total cholesterol 160 to 240 mg/dL and triglycerides <350 mg/dL
19. Prevention of coronary heart disease in clinical practice: Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
20. The role of oxidized lipoprotein in atherogenesis
21. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase
22. Differential effects of smoking on myocardial infarction risk according the Gln/Arg variants of the human paraoxonase gene
23. Paraoxonase gene polymorphisms are associated with carotid arterial wall thickness in subjects with familial hypercholesterolemia
24. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction
25. Serum paraoxonase after myocardial infarction
26. Serum paraoxonase activity in familial hypercholesterolemia and insulin-dependent diabetes mellitus
27. Effect of simvastatin therapy on paraoxonase activity and related lipoproteins in familial hypercholesterolemic patients
28. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus
29. Modulated serum activities and concentrations of paraoxonase in high density lipoprotein deficiency states
30. Overexpression of apolipoprotein All in transgenic mice converts high density lipoproteins to proinflammatory particles
31. Paraoxonase protection of LDL against peroxidation is independent of its esterase activity towards paraoxon and is unaffected by the Q→R genetic polymorphism
32. Human serum paraoxonase (PON1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants
33. Oxidative status of lipoproteins in coronary disease patients
34. Paraoxonase polymorphism Met-Leu54 is associated with modified concentrations of the enzyme: A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes
35. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations
36. Minimum sample size to detect gene-environment interaction in case-control designs